Adavivint

Cat. No.: OB0225WX-1689

Appearance: Solid

Purity: ≥98%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Adavivint is a high-potency inhibitor of the canonical Wnt signaling pathway, demonstrating an EC50 of 19.5 nM in TCF/LEF reporter gene assays conducted in SW480 cells.

Synonym: Adavivint (SM04690); 1467093-03-3; lorecivivint; N-(5-(3-(7-(3-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide; N-(5-(3-(7-(3-Fluorophenyl)-3H-imidazo(4,5-C)pyridin-2-yl)-1H-indazol-5- yl)-pyridin-3-yl)-3-methylbutanamide; N-(5-{3-[7-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl}pyridin-3-yl)-3-methylbutanamide; N-(5-{3-[7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl}pyridin-3-yl)-3-methylbutanamide; N-[5-[3-[7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl]pyridin-3-yl]-3-methylbutanamide; N-(5-((3Z)-3-(7-(3-fluorophenyl)imidazo(4,5-c)pyridin-2-ylidene)-1,2-dihydroindazol-5-yl)pyridin-3-yl)-3-methylbutanamide

CAS No.: 1467093-03-3

Compound CID: 135565709

Formula: C₂₉H₂₄FN₇

Formula Weight: 505.55

Specification

Targets&IC50: Wnt (SW480 cells): 19.5 nM (EC50)

Relative Density: 1.365 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Adavivint is utilized in regenerative medicine and musculoskeletal research as a Wnt pathway modulator to examine its role in promoting chondrogenesis and tissue repair.